Loading...

NVRT

NVS

NOVARTIS AG

(NVS)

2025 6-K

Novartis Filing

4 Feb '26

Q4 2025 Financials

4 Feb '26

FDA Approval Announcement

24 Nov '25

Sales Growth Outlook

20 Nov '25

Debt Securities Issuance

5 Nov '25

Financial Report Issued

28 Oct '25

Novartis Acquisition

27 Oct '25

FDA Approval Announcement

30 Sep '25

Positive Trial Results

11 Aug '25

Management Change

17 Jul '25

Novartis Filing Update

17 Jul '25

Pluvicto Update

2 Jun '25

Q1 Financial Report

29 Apr '25

FDA Approval Announcement

2 Apr '25

FDA Approval Update

28 Mar '25

Filing Reported

31 Jan '25

Financial Report

31 Jan '25

Positive Study Results

30 Dec '24

Guidance Upgrade

25 Nov '24

FDA Approval Scemblix

29 Oct '24

Q3 2024 Report

29 Oct '24

Debt Issuance Report

18 Sep '24

FDA Approval Announcement

17 Sep '24

FDA Approval

7 Aug '24

Financial Report Filing

18 Jul '24

Novartis Filing

23 Apr '24

Filing Announcement

31 Jan '24

Q4 2023 Financials

31 Jan '24

Positive Trial Results

8 Jan '24

External Links:

SEC

Novartis AG submitted a 6-K filing on July 17, 2025, reporting their Q2 2025 Financial Report and Interim Financial Report. This filing is significant as it provides insight into the company's financial performance.

AI Assistant

NOVARTIS AG

2025

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.